PMID- 37655831
OWN - NLM
STAT- Publisher
LR  - 20231001
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 32
IP  - 11
DP  - 2023 Nov
TI  - Moxifloxacin monotherapy for treatment of uncomplicated pelvic inflammatory 
      disease: A systematic review and meta-analysis with trial sequential analysis of 
      randomized controlled trials.
PG  - 1189-1199
LID - 10.1002/pds.5677 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the efficacy and safety of 
      moxifloxacin monotherapy for the treatment of uncomplicated pelvic inflammatory 
      disease (uPID). METHODS: The literatures from PubMed, ScienceDirect, Google 
      Scholar, Cochrane library and the http://clinicaltrials.gov/ were retrieved until 
      February 2023. Only randomized controlled trials (RCTs) comparing the efficacy 
      and safety of moxifloxacin with other antibiotics for treating uPID were 
      included. The primary outcomes were clinical cure rate (CCR), bacteriological 
      success rates (BSR) and risk of drug-related adverse events (AEs). We used 
      random-effects modelled meta-analysis, trial sequential analysis, and the Grading 
      of Recommendations Assessment, Development, and Evaluation. This study was 
      registered in the International Prospective Register of Systematic Reviews 
      (registration number: CRD42023428751). RESULTS: A total of four RCTs that 
      enrolled 3201 women patients with uPID were included. In the per-protocol 
      populations, no significant difference was observed between patients given 
      moxifloxacin and those given other antibiotics with regard to CCR at test-of-cure 
      (TOC) (2485 patients, odds ratio [OR] = 0.84, 95% confidence interval [CI] 
      0.68-1.04, p = 0.12). Similarly, there was no statistically significant 
      difference between patients given moxifloxacin and those given other antibiotics 
      in terms of BSR at TOC (471 patients, OR = 1.17, 95% CI 0.70-1.96, p = 0.56) in 
      the microbiologically valid population. However, drug-related AEs occurred less 
      frequently with moxifloxacin than with other antibiotics (2973 patients, 
      OR = 0.74, 95% CI 0.64-0.86, p < 0.0001), especially gastrointestinal AEs (2973 
      patients, OR = 0.59, 95% CI 0.47-0.74, p < 0.00001). CONCLUSIONS: In the 
      treatment of uPID, moxifloxacin monotherapy can achieve similar efficacy as other 
      combination therapy regimens. Moreover, moxifloxacin had a better safety profile 
      than that of comparators. Based on its additional advantages (i.e., better safety 
      profile, no dosage adjustment and better compliance), moxifloxacin may be a more 
      fascinating option compared with the currently used regimens.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Pharmacy, Zhongshan People's Hospital, Zhongshan, China.
FAU - Dong, Qin
AU  - Dong Q
AD  - Department of Pharmacy, Zhongshan People's Hospital, Zhongshan, China.
FAU - Hong, Weilan
AU  - Hong W
AD  - Department of Pharmacy, Zhongshan People's Hospital, Zhongshan, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Department of Pharmacy, Zhongshan People's Hospital, Zhongshan, China.
FAU - Li, Yingran
AU  - Li Y
AD  - Department of Pharmacy, Zhongshan People's Hospital, Zhongshan, China.
LA  - eng
GR  - None/
PT  - Journal Article
PT  - Review
DEP - 20230901
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
SB  - IM
OTO - NOTNLM
OT  - meta-analysis
OT  - moxifloxacin
OT  - uncomplicated pelvic inflammatory disease
EDAT- 2023/09/01 12:43
MHDA- 2023/09/01 12:43
CRDT- 2023/09/01 08:32
PHST- 2023/07/03 00:00 [revised]
PHST- 2023/03/01 00:00 [received]
PHST- 2023/07/28 00:00 [accepted]
PHST- 2023/09/01 12:43 [pubmed]
PHST- 2023/09/01 12:43 [medline]
PHST- 2023/09/01 08:32 [entrez]
AID - 10.1002/pds.5677 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2023 Nov;32(11):1189-1199. doi: 10.1002/pds.5677. 
      Epub 2023 Sep 1.